Maintenance notice: Some features that submit or update information are temporarily disabled while we migrate the website. You can continue browsing normally. Thank you for your understanding.
TUESDAY, April 21, 2015 (HealthDay News) -- Arthritis medications known as biologic disease-modifying drugs can cost Medicare patients more than $2,700 in co-payments a year, a new report finds.
Researchers say the tab is an immense burden on patients with disabling conditions such as rheumatoid arthritis, a chronic disorder that affects an estimated 1.3 million Americans.
Biologic anti-rheumatic medications -- which include drugs such as adalimumab (Humira), anakinra (Kineret) and etanercept (Enbrel) -- have allowed patients to gain better control of rheumatoid arthritis when taken early in the course of disease, the researchers explained.
Improving orthopaedic care, education and research using Internet technologies